Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY |
| 23 |
| Jul 17, 2025 |
| clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | CelgeneINDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT01303887 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients(PACIFICO) | completed | Phase 3 | 680 | University of LiverpoolOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 37 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
| NCT01539083 | Velcade (Bortezomib) Consolidation After Transplant(VCAT) | completed | Phase 3 | 256 | Janssen Scientific Affairs, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03366272 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients(NIVEAU) | completed | Phase 2 / Phase 3 | 348 | Universität des SaarlandesOTHER | 8 | Jan 28, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT02406092 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | completed | Phase 3 | 139 | Hoffmann-La RocheINDUSTRY | 3 | Nov 21, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT01093196 | Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients | completed | Phase 3 | 660 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01091831 | Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects | completed | Phase 3 | 389 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03053440 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)(ASPEN) | completed | Phase 3 | 201 | BeiGeneINDUSTRY | 12 | Oct 26, 2024 | clinicaltrials |
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | completed | Phase 3 | — | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma(ILyAD) | completed | Phase 3 | 211 | Jonathan FriedbergOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00991211 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | completed | Phase 3 | 549 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01456351 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | completed | Phase 3 | 230 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT00551928 | Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients(MPRvsMEL200) | completed | Phase 3 | 402 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02215980 | STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS | completed | Phase 3 | 210 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03952091 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 289 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Jul 3, 2024 | clinicaltrials |
| NCT03234972 | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 2 | May 29, 2024 | clinicaltrials |
| NCT01788020 | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | completed | Phase 3 | 202 | University of UlmOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 462 | University College, LondonOTHER | 3 | May 9, 2024 | clinicaltrials |
| NCT00678327 | Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma | completed | Phase 3 | 1,202 | University College, LondonOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | completed | Phase 3 | 372 | Kyowa Kirin, Inc.INDUSTRY | 11 | Apr 25, 2024 | clinicaltrials |
| NCT03217812 | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | completed | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT00877656 | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | completed | Phase 2 / Phase 3 | 21 | Emergent BioSolutionsINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT03265574 | PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?(PROACT) | completed | Phase 3 | 111 | South Tees Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT00075946 | Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | completed | Phase 3 | 545 | Eastern Cooperative Oncology GroupNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03976102 | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma(FLINTER) | completed | Phase 3 | 317 | Dr. Reddy's Laboratories LimitedINDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04361279 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 421 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02369016 | Phase III Copanlisib in Rituximab-refractory iNHL(CHRONOS-2) | completed | Phase 3 | 25 | BayerINDUSTRY | 10 | Nov 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2025source: clinicaltrials